Shionogi & Co Ltd (SGIOF) Q1 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for your participation out of your very busy schedule. So we would like to start the first quarter closing meeting explanation. So I'd like to introduce the speakers today. So first of all, Mr. John Keller, Dr. Sinclair, Senior Executive Officer, Senior Vice President, R&D Sponsor Advisory Unit. And next, Dr. Toshinobu Iwasaki, Senior Executive Officer, Senior Vice President, Healthcare Business Supervisor Unit in the Pharmaceutical Commercial Department. And then, Dr. Koji Hanasaki, Executive Officer, Senior Vice President, Supply Supervisor Unit in the Global Business Division. Next, Noriyuki Kishida, Senior Executive Officer, Senior Vice President in Corporate Supervisory Unit, and Dr. Ryuichi Kiyama, Senior Executive Officer, Senior Vice President, Corporate Strategy Division, Dr. Takeki Uehara, Corporate Officer, Senior Vice President, Direct Development and Regulatory Science Division, and last, Ms. Masako Kudo. Vice President of Financial Accounting Department and Corporate Strategy Division. And first, Ms. Kuro will explain about the overview of the closing and Kiyama will explain the major activities and achievements for the first quarter. And then after that, we take a question and answer time. And we'd like to close at 7.30. 15, the maximum. So you can use the simultaneous interpretation function today. So in case you use the simultaneous interpretation, please find the global icon in the bottom of the screen and you can choose either English or Japanese. So let me start right away. So Ms. Kuro, please. So I am Kudo. I would like to explain the overview of the first quarter financial result. So on page 4, this is a highlight of the financial result. So for the first quarter of this year ended in 109.3 billion yen operating profit of 46....